Health Care Sector Update for 11/01/2018: MOR,SNN,TEVA,PKI

Shutterstock photo

Top Health Care Stocks

JNJ +0.61%

PFE +1.26%

ABT +1.54%

MRK -1.11%

AMGN +0.12%

Health care stocks advanced today, including a more than 0.9% gain for the NYSE Health Care Index in recent trade. Also, shares of health care companies in the S&P 500 also were up over 1.1% as a group while the Nasdaq Biotechnology index was ahead nearly 3.8% today.

Among health care stocks moving on news:

(+) MorphoSys AG ( MOR ) was more than 16% higher this afternoon after the therapeutic antibody drugmaker said it will present data from Phase I and Phase IIa testing of its MOR202 and MOR208 hemato-oncological drug candidates at the annual meeting of the American Society of Hematology early next month in San Diego. In one study designed to measure the efficacy and safety of a combination of the company's Fc-enhanced CD19 antibody MOR208 in combination with the chemotherapy drug lenalidomide, 35% of the trial participants with relapsed or refractory diffuse large B cell lymphoma experienced a complete responses while another 25% had partial responses, producing an overall response rate of 58%, the company said in an abstract for a Dec. 1 presentation.

In other sector news:

(+) Teva Pharmaceutical Industries ( TEVA ) was more than 12% higher in recent trading after the drugmaker reported adjusted Q3 net income of $0.68 per American depository share, down from $1.00 per ADS and topping the Capital IQ consensus by $0.14 per share. Total revenue slid to $4.53 billion from $5.62 billion last year, roughly in-line with the $4.54 billion analyst mean. The company also raised its FY18 outlook to a new range of $2.80 to $2.95 per share from its prior guidance expecting between $2.55 to $2.80 per share and also exceeding the Street view by at least $0.02 per share.

(+) Smith & Nephew ( SNN ) has slowly extended its gain by Thursday afternoon, rising more than 8% after the medical device company announced improved Q3 revenue, advancing 2% over year-ago levels on a reported basis to $1.17 billion. U.S. sales grew 4% year-over-year during the September quarter while emerging-market sales jumped 10%. There was a 1% sales decline for other established markets, it said. Looking forward, the company is projecting a 3% to 4% in FY18 sales over the prior-year period. The company did not provide Q3 earnings and analyst estimates also were not available for comparison.

(-) PerkinElmer's ( PKI ) declined Thursday, falling as much as 9%, after the medical diagnostics company reported adjusted Q3 net income of $0.90 per share, improving on a $0.73 per share during the year-ago period but still missing the Capital IQ consensus by $0.02 per share. Revenue rose to $674.3 million from $554.3 million a year ago but also came up shy of the $676.72 million analyst mean. The company also lowered its FY18 earnings forecast by $0.05 per share, now expecting non-GAAP net income of $3.60 per share, also trailing the $3.66 per share Street view.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.

This article appears in: Investing , US Markets
Referenced Symbols: MOR , TEVA , SNN , PKI

More from MT Newswires


MT Newswires

MT Newswires

Market News, Commodities

Research Brokers before you trade

Want to trade FX?